Eli Lilly's $300M Oncology Play: Inside the CrossBridge Bio Acquisition and the 2026 Biotech M&A Pipeline

Eli Lilly is reportedly moving to acquire the cancer-focused biotech firm CrossBridge Bio in a deal valued at up to $300 million, a strategic move to bolster its oncology portfolio. The purported acquisition, discussed by Portal Innovations CEO John Flavin on Bloomberg's "The Close," signals a targeted investment in a high-stakes therapeutic area, reflecting the continued appetite of major pharma for innovative assets to fuel growth.

Flavin provided a rare insider's look at the transaction's mechanics and its place within the broader 2026 biotech merger and acquisition pipeline. The deal underscores the premium placed on promising oncology platforms, as large-cap companies like Lilly seek to secure new pipelines amid patent cliffs and competitive pressures. The discussion with hosts Katie Greifeld and Romaine Bostick moved beyond this single deal to analyze the trends shaping future biotech consolidation.

The acquisition, if finalized, would immediately augment Lilly's cancer treatment segment, an area of intense research and commercial competition. Flavin's commentary suggests this is a bellwether for the year ahead, where strategic, bolt-on acquisitions in specialized fields like oncology are expected to drive significant deal flow. The activity points to sustained pressure on smaller biotechs to demonstrate clear clinical pathways to attract premium bids from deep-pocketed pharmaceutical giants.